The Affiliated Hospital of Inner Mongolia Medical University Hohhot 010010 China;
Department of Pharmacology of Pharmaceutical College Inner Mongolia Medical University Hohhot 010010 China;
The Center for New Drug Safety Evaluation and Research of Inner Mongolia Medical University Hohhot 010010 ChinaInner Mongolia Research Center for Drug Screening Hohhot 010110 China;
The Affiliated Hospital of Inner Mongolia Medical University Hohhot 010010 China;
The Center for New Drug Safety Evaluation and Research of Inner Mongolia Medical University Hohhot 010010 ChinaInner Mongolia Research Center for Drug Screening Hohhot 010110 China;
Department of Pharmacology of Pharmaceutical College Inner Mongolia Medical University Hohhot 010010 ChinaInner Mongolia Research Center for Drug Screening Hohhot 010110 China;
Department of Pharmacology of Pharmaceutical College Inner Mongolia Medical University Hohhot 010010 ChinaInner Mongolia Research Center for Drug Screening Hohhot 010110 China;
Department of Pharmacology of Pharmaceutical College Inner Mongolia Medical University Hohhot 010010 ChinaInner Mongolia Research Center for Drug Screening Hohhot 010110 China;
The Center for New Drug Safety Evaluation and Research of Inner Mongolia Medical University Hohhot 010010 ChinaInner Mongolia Research Center for Drug Screening Hohhot 010110 China;
Department of Pharmacology of Pharmaceutical College Inner Mongolia Medical University Hohhot 010010 ChinaThe Center for New Drug Safety Evaluation and Research of Inner Mongolia Medical University Hohhot 010010 ChinaInner Mongolia Research Center for Drug Screening Hohhot 010110 China;
liver cancer; fragile histidine triad; T-cadherin/H-cadherin; methylation; susceptibility;